Related Experiment Video
Updated: Jul 29, 2026
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Systematic analysis reveals a pan-cancer SNHG family signature predicting prognosis and immunotherapy response
Haotian Zheng1, Guanghui Wang2, Yadong Wang1
1Institute of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, China.
Abstract:
Small nucleolar RNA host genes (SNHGs) are a special family of long non-coding RNAs (lncRNAs), which not only function in a way similar to other lncRNAs but also influence the intracellular level of small nucleolar RNAs to modulate cancers. However, the features of SNHGs and their role in the prognosis and immunotherapeutic response of human cancer have not been explored. We found that SNHGs were commonly deregulated and correlated with patient survival in various cancers. The critical role of DNA methylation and somatic alterations on deregulation was also identified. SNHG family score was significantly associated with survival, multiple tumor characteristics, and tumor microenvironment. SNHG-related risk score could serve as a prognostic and immunotherapeutic response biomarker based on multiple databases. This study emphasizes the potential of SNHGs as biomarkers for prognosis and immunotherapeutic response, enabling further research into the immune regulatory mechanism and therapeutic potentials of SNHGs in cancer.
Insights
Small nucleolar RNA host genes (SNHGs) are deregulated in cancers and impact patient survival. SNHG scores show potential as biomarkers for cancer prognosis and predicting response to immunotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small nucleolar RNA host genes (SNHGs) are long non-coding RNAs (lncRNAs) involved in cancer modulation.
- The specific roles of SNHGs in human cancer prognosis and immunotherapeutic response remain largely unexplored.
Purpose of the Study:
- To investigate the deregulation patterns of SNHGs across various human cancers.
- To evaluate the potential of SNHGs as prognostic and immunotherapeutic biomarkers.
Main Methods:
- Analysis of SNHG expression data across multiple cancer types.
- Correlation analysis between SNHG expression, patient survival, and clinical characteristics.
- Investigation of DNA methylation and somatic alterations affecting SNHG deregulation.
- Development and validation of SNHG-based risk scores using public databases.
Main Results:
- SNHGs are frequently deregulated and associated with patient survival in diverse cancers.
- DNA methylation and somatic alterations contribute to SNHG deregulation.
- An SNHG family score correlates significantly with survival, tumor characteristics, and the tumor microenvironment.
- An SNHG-related risk score demonstrates potential as a biomarker for prognosis and immunotherapy response.
Conclusions:
- SNHGs are commonly dysregulated in cancer and linked to patient outcomes.
- SNHG-based scores show promise as predictive biomarkers for cancer prognosis and immunotherapy.
- Further research into SNHGs could uncover novel immune regulatory mechanisms and therapeutic strategies in oncology.
